GIVLAARI SOLUTION

Land: Kanada

Språk: engelska

Källa: Health Canada

Aktiva substanser:

GIVOSIRAN (GIVOSIRAN SODIUM)

Tillgänglig från:

ALNYLAM NETHERLANDS B.V.

ATC-kod:

A16AX16

INN (International namn):

GIVOSIRAN

Dos:

189MG

Läkemedelsform:

SOLUTION

Sammansättning:

GIVOSIRAN (GIVOSIRAN SODIUM) 189MG

Administreringssätt:

SUBCUTANEOUS

Enheter i paketet:

15G/50G

Receptbelagda typ:

Prescription

Terapiområde:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

Produktsammanfattning:

Active ingredient group (AIG) number: 0162538001; AHFS:

Bemyndigande status:

APPROVED

Tillstånd datum:

2020-10-09

Produktens egenskaper

_GIVLAARI (givosiran) _
_ _
_ _
_Page 1 of 29_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
GIVLAARI®
Givosiran Injection
Solution, 189 mg/mL givosiran (as givosiran sodium), subcutaneous
injection
Various alimentary tract and metabolism products
Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands
Imported / Distributed by:
Innomar Strategies Inc.
Oakville, ON
L6L 0C4
Date of Initial Authorization:
OCT 08, 2020
Date of Revision:
SEPT 18, 2023
Submission Control Number: 275066
_ _
_ _
_ _
_GIVLAARI (givosiran) _
_Page 2 of 29_
RECENT MAJOR LABEL CHANGES
Not applicable. TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
.............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................ 4
4.4
Administration
.........................................................................................................
5
4.5
Missed Dose
.............................................................................................................
6
5
OVERDOSAGE
.................................................................